Corellation of Mutations, TILs and Age in Breast Cancer

Hellenic Cooperative Oncology Group345 enrolled

Overview

Age may pertain to different tumor genotype characteristics which may interfere with treatment efficacy and prognosis. The investigators investigated the distribution and prognostic effect of mutations (mut) and tumor infiltrating lymphocyte (TILs) in young and elderly early breast cancer patients (pts).

Study Type

OBSERVATIONAL

Enrollment

345

Conditions

Breast Cancer

Interventions

Corellation of Mutations, TILs and Age in Breast CancerGENETIC

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * women with early breast cancer \<35 years old or \>65 years old Exclusion Criteria: * NA

Outcomes

Primary Outcomes

Assessment of the prevalence of gene mutations in women <=35 years old with early breast cancer.

Time frame: Up to 13 years

Assessment of the prevalence of gene mutations in women >65years old with early breast cancer.

Time frame: Up to 13 years

Evaluation of Tumor Infiltrating Lymphocytes (TILs) density using descriptive statistics in women <=35 years old with early breast cancer.

Time frame: Up to 13 years

Evaluation of Tumor Infiltrating Lymphocytes (TILs) density using descriptive statistics in women >65 years old with early breast cancer.

Time frame: Up to 13 years

Evaluation of the prognostic effect of gene mutations and Tumor Infiltrating Lymphocytes with respect to Overall Survival in women <=35 years old with early breast cancer

Time frame: Up to 13 years

Evaluation of the prognostic effect of gene mutations and Tumor Infiltrating Lymphocytes with respect to Overall Survival in women >65 years old with early breast cancer.

Time frame: Up to 13 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.